Murine study identifies critical neonatal window when microbiota disruption results in lifelong metabolic consequences stemming from reduced β cell development.

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...

Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...